JP2021520392A5 - - Google Patents
Info
- Publication number
- JP2021520392A5 JP2021520392A5 JP2020554834A JP2020554834A JP2021520392A5 JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5 JP 2020554834 A JP2020554834 A JP 2020554834A JP 2020554834 A JP2020554834 A JP 2020554834A JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- triazolo
- pyrazolo
- pyrimidine
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/082140 | 2018-04-08 | ||
| CN2018082140 | 2018-04-08 | ||
| PCT/CN2019/081785 WO2019196803A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021520392A JP2021520392A (ja) | 2021-08-19 |
| JP2021520392A5 true JP2021520392A5 (enExample) | 2022-04-07 |
Family
ID=68163465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554834A Withdrawn JP2021520392A (ja) | 2018-04-08 | 2019-04-08 | Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11472811B2 (enExample) |
| EP (1) | EP3774813A4 (enExample) |
| JP (1) | JP2021520392A (enExample) |
| KR (1) | KR20200140849A (enExample) |
| CN (1) | CN112313234B (enExample) |
| AU (1) | AU2019251148A1 (enExample) |
| BR (1) | BR112020020078A2 (enExample) |
| CA (1) | CA3095839A1 (enExample) |
| EA (1) | EA202092036A1 (enExample) |
| IL (1) | IL277744A (enExample) |
| MX (1) | MX2020010618A (enExample) |
| SG (1) | SG11202009706VA (enExample) |
| TW (1) | TW202010500A (enExample) |
| WO (1) | WO2019196803A1 (enExample) |
| ZA (1) | ZA202005772B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| US12552799B2 (en) | 2020-03-26 | 2026-02-17 | Nxera Pharma Uk Limited | Triazolone compounds |
| WO2022087146A1 (en) | 2020-10-22 | 2022-04-28 | Landos Biopharma, Inc. | Lancl ligands |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| BR0213172A (pt) | 2001-10-08 | 2004-09-14 | Hoffmann La Roche | Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| ATE461932T1 (de) | 2004-04-21 | 2010-04-15 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| CN103261202B (zh) | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| CN110742893B (zh) | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
-
2019
- 2019-04-08 KR KR1020207031434A patent/KR20200140849A/ko not_active Ceased
- 2019-04-08 TW TW108112189A patent/TW202010500A/zh unknown
- 2019-04-08 WO PCT/CN2019/081785 patent/WO2019196803A1/en not_active Ceased
- 2019-04-08 EP EP19785064.7A patent/EP3774813A4/en not_active Withdrawn
- 2019-04-08 AU AU2019251148A patent/AU2019251148A1/en not_active Abandoned
- 2019-04-08 MX MX2020010618A patent/MX2020010618A/es unknown
- 2019-04-08 CN CN201980024422.3A patent/CN112313234B/zh not_active Expired - Fee Related
- 2019-04-08 CA CA3095839A patent/CA3095839A1/en active Pending
- 2019-04-08 EA EA202092036A patent/EA202092036A1/ru unknown
- 2019-04-08 JP JP2020554834A patent/JP2021520392A/ja not_active Withdrawn
- 2019-04-08 US US16/982,681 patent/US11472811B2/en active Active
- 2019-04-08 BR BR112020020078-6A patent/BR112020020078A2/pt not_active IP Right Cessation
- 2019-04-08 SG SG11202009706VA patent/SG11202009706VA/en unknown
-
2020
- 2020-09-17 ZA ZA2020/05772A patent/ZA202005772B/en unknown
- 2020-10-01 IL IL277744A patent/IL277744A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500345A5 (enExample) | ||
| JP2008534496A5 (enExample) | ||
| JP2022554169A5 (enExample) | ||
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| AU2012266369B2 (en) | Pyridin- 2 -amides useful as CB2 agonists | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2008148902A (ru) | Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3) | |
| JP2013542265A5 (enExample) | ||
| JP2023525762A5 (enExample) | ||
| JP2023520843A5 (enExample) | ||
| JP2009542638A5 (enExample) | ||
| JP2009542721A5 (enExample) | ||
| JP2016536333A5 (enExample) | ||
| JP2018511587A5 (enExample) | ||
| JP2004525157A5 (enExample) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2022552655A5 (enExample) | ||
| JP2018530591A5 (enExample) | ||
| RU2011137399A (ru) | Гетероциклическое производное | |
| JP2017500364A5 (enExample) | ||
| JP2017523215A5 (enExample) | ||
| RU2017139727A (ru) | Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования | |
| RU2018127315A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний | |
| RU2019119899A (ru) | Новое дизамещенное 1,2,4-триазиновое соединение |